In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
News|Podcasts|September 18, 2026
ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new feature article , we examined why "patient voice" has become an empty phrase when industry embeds it too late and without clear ownership. Genuine patient-centeredness requires input before endpoints are chosen and protocols are written, not consultative review after structure is locked. The cost of misalignment shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about. - In a
contributed article , Rama Kondru, CEO of Emmes Group, examined lessons from hundreds of trials showing that AI's next bottleneck is not the model but the system around it. Faster individual tasks do not shorten trials unless decisions and workflows are connected end-to-end, requiring standardized data, governed definitions, and clear accountability for whole-trial outcomes rather than fragmented handoffs. - In another
contributed article , Julie Ross examined how regulatory expectations for patient input have shifted from aspiration to documented methodology across the FDA, EU, and UK through four PFDD guidances, ICH E6(R3), and new statutory requirements. Large-scale, structured, patient-reported data can sharpen hypotheses about what matters to patients early in planning, but cannot substitute for the representative sampling and psychometric rigor those guidances require.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
Trending on Applied Clinical Trials Online
1
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
2
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
3
ACT Brief: FDA Transparency Roadmap, Radiopharmaceutical Trial Operations, and AI-Powered Enrollment Prediction
4
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
5